Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 13/20 | 0.53 |
| ▸ | F13A1 | P00488 | 10/20 | 0.53 |
| ▸ | TGM1 | P22735 | 7/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | NUDT15 | Q9NV35 | 1/20 | 0.46 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5327420 | 0.84 | TGM2 (0.52) | TGM2F13A1TGM1LMNA | |
| SCHEMBL6790392 | 0.82 | PKM (0.65) | TGM2F13A1TGM1PKMLMNA | |
| SCHEMBL5202414 | 0.81 | STS (0.57) | TGM2F13A1TGM1TGM3MAPT | |
| SCHEMBL5736659 | 0.81 | F10 (0.57) | TGM2F13A1TGM1PKM | |
| SCHEMBL3210642 | 0.80 | TGM2 (0.59) | TGM2F13A1TGM1TGM3STS | |
| SCHEMBL3044686 | 0.79 | GHSR (0.60) | — | |
| SCHEMBL29979105 | 0.79 | MAPT (0.54) | LMNAHTTMAPT | |
| SCHEMBL1226103 | 0.79 | MAPT (0.54) | LMNAHTTMAPT | |
| SCHEMBL2822894 | 0.78 | TGM2 (0.43) | TGM2F13A1TGM1TGM3MAPT | |
| SCHEMBL18410584 | 0.78 | TGM2 (0.65) | TGM2F13A1TGM1PKMHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214495-A1 | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| US-20080200431-A1 | 6-{4-[4-(3-Chloro-1H-indole-6-sulfonyl)-3-hydroxy-piperazine-1-carbonyl]-piperidin-1-yl}-2-methyl-2H-pyridazin-3-one for example; antithrombotic and anticoagulant; synthesis; combination therapy | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
| WO-2007008146-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF FACTOR XA | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007008143-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF FACTOR XA | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200431-A1 | 6-{4-[4-(3-Chloro-1H-indole-6-sulfonyl)-3-hydroxy-piperazine-1-carbonyl]-piperidin-1-yl}-2-methyl-2H-pyridazin-3-one for example; antithrombotic and anticoagulant; synthesis; combination therapy | CYC1, F2, CBR1 | TGM2 4220/4885F13A1 191/4885TGM1 2092/4885 |
| US-20080214495-A1 | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa | F10, F12, F11 | TGM2 4127/4885F13A1 16/4885TGM1 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.